Country: Canada
Language: English
Source: Health Canada
DOXORUBICIN HYDROCHLORIDE
SANDOZ CANADA INCORPORATED
L01DB01
DOXORUBICIN
2MG
SOLUTION
DOXORUBICIN HYDROCHLORIDE 2MG
INTRAVENOUS
5/25/100ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0110825002; AHFS:
CANCELLED POST MARKET
2021-04-21
_ _ _Doxorubicin Hydrochloride Injection _ _Page 1 of 46_ PRODUCT MONOGRAPH PR DOXORUBICIN HYDROCHLORIDE INJECTION doxorubicin hydrochloride 2 mg/mL 10 mg (5 mL), 50 mg (25 mL) and 200 mg (100 mL) Vials Manufacturer’s Standard ANTINEOPLASTIC AGENT Sandoz Canada Inc. 110 rue de Lauzon Boucherville, Quebec J4B 1E6 Date of Revision: June 26, 2019 Submission Control No: 228706 _ _ _Doxorubicin Hydrochloride Injection _ _Page 2 of 46_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ............................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 16 STORAGE AND STABILITY ......................................................................................... 17 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 19 PART II: SCIENTIFIC INFORMATION .............................................................................. 20 PHARMACEUTICAL INFORMATION ......................................... Read the complete document